


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

Claims 1-22. (canceled)

23. (new) A method of treating wet age-related macular degeneration, which comprises administering to a patient in need thereof a therapeutically effective amount of 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione having the formula:



or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.

24. (new) The method of claim 23, wherein the compound is 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione.

25. (new) The method of claim 23, wherein the compound is a pharmaceutically acceptable salt.

26. (new) The method of claim 23, wherein the compound is a pharmaceutically acceptable solvate.

27. (new) The method of claim 23, wherein the compound is a pharmaceutically acceptable stereoisomer.

28. (new) The method of claim 27, wherein the stereoisomer is an enantiomerically pure R isomer.

29. (new) The method of claim 27, wherein the stereoisomer is an enantiomerically pure S isomer.

30. (new) The method of claim 23, which further comprises administering a therapeutically effective amount of a second active agent.

31. (new) The method of claim 30, wherein the second active agent is a steroid, a light sensitizer, an integrin, an antioxidant, an interferon, a xanthine derivative, a growth hormone, a neurotrophic factor, a regulator of neovascularization, an anti-VEGF antibody, a prostaglandin, an antibiotic, a phytoestrogen, an anti-inflammatory compound or an antiangiogenesis compound.

32. (new) The method of claim 30, wherein the second active agent is thalidomide, verteporfin, purlytin, an angiostatic steroid, rhuFab, interferon-2 α or pentoxifylline, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

33. (new) The method of claim 32, wherein the second active agent is thalidomide.

34. (new) The method of claim 23, wherein the compound is administered before, during or after surgical intervention.

35. (new) The method of claim 34, wherein the surgical intervention is light therapy, laser therapy, radiation therapy, retinal pigment epithelium transplantation, or foveal translocation.

36. (new) The method of claim 23, wherein the compound is administered orally.

37. (new) The method of claim 36, wherein the compound is administered in the form of a capsule or tablet.

38. (new) The method of claim 37, wherein the compound is administered in an amount of from about 0.10 to about 150 mg per day.

39. (new) The method of claim 38, wherein the compound is administered in an amount of from about 0.1 to about 1 mg per day.

40. (new) The method of claim 23, wherein the compound is administered cyclically.